

## FINANCIAL TEAR SHEET

### Corporate Profile

Adaptimmune is a leader in the TCR T-cell therapy space focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets - whether intracellular or surface expressed - for administration to patients. We engineer TCRs to increase their affinity to cancer-specific peptides in order to target and potentially destroy cancer cells in patients.

Our wholly-owned pipeline of SPEAR T-cell therapies and targets continues to evolve; SPEAR T-cell therapies targeting MAGE-A10, MAGE-A4, AFP and NY-ESO are moving into and through clinical studies. In addition to the targets for which clinical and preclinical evaluation is ongoing, we continue to build a pipeline of proprietary TCR therapeutic candidates: We have identified over 25 intracellular target peptides preferentially expressed in cancer cells and are currently progressing 12 through unpartnered research programs. We believe these research programs are relevant to a wide range of cancer indications.

We believe our approach will lead to SPEAR therapeutic candidates that have the potential to significantly impact cancer treatment and the clinical outcomes of patients with cancer.

### Primary IR Contact

Investor Contact

**Email:**


[IR@adaptimmune.com](mailto:IR@adaptimmune.com)

# Stock Performance

## ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$5.32</b>
Change (%)	▲ 0.02 (0.38%)
Volume	202,202
52 Week Low	\$3.76
Market Cap	\$2,984,394,608
Rolling EPS	-1.10
PE Ratio	0
Shares Outstanding	560,976,430

Data as of 05/26/17 4:00 p.m. ET



## Recent Headlines & Events

05/26/17

[Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology \(ASCO\) Annual Meeting](#)

05/25/17

[Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® \(pembrolizumab\) in Multiple Myeloma](#)

05/16/17

[Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors](#)

DATE	TITLE
06/06/17 8:00 a.m. ET	<a href="#"><u>Adaptimmune Data Update on NY-ESO SPEAR T-cells in Synovial Sarcoma; ASCO 2017</u></a>

## SEC Filings

## Corporate Governance

[James Noble](#)

Chief Executive Officer

<b>FILING DATE</b>	<b>FORM</b>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
05/26/17	<u>8-K</u>	<u>Helen Tayton-Martin, PhD, MBA</u>	Chief Operating Officer
05/25/17	<u>8-K</u>	<u>Rafael Amado, MD</u>	Chief Medical Officer
05/16/17	<u>8-K</u>	<u>Bent Jakobsen, PhD</u>	Scientific Co-Founder
05/15/17	<u>CTORDER</u>	<u>Gwendolyn Binder-Scholl, PhD</u>	Chief Technology Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.